A US judge has invalidated pharmaceutical company Bristol-Myers Squibb (BMS)’s patent covering its hepatitis B treatment Baraclude, agreeing with generic manufacturer Teva Pharmaceuticals that the invention of the active compound in the drug was obvious to anyone skilled in medicinal chemistry.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Bristol-Myers, Teva, Baraclude, patent, generic, invalid, obvious
